– Company to host live webcast and conference call Monday, December 15, 2025 at 8:00 am ET – EMERYVILLE, Calif., Dec. 14, 2025 (GLOBE NEWSWIRE) — Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, announced it will host a live webcast and conference call on Monday, December 15, 2025 at 8:00 am ET to review topline results from the registrational Phase 2 KYSA-8 clinical trial evaluating KYV-101 in stiff person syndrome (SPS). Conference Call Details Participants will need to register at the below-noted URL in order to listen and participate in the call. Once registered, participants will receive a dial-in phone number and unique PIN number which will be needed to join the call. The call can also be accessed via live webcast....

 Update on the Flamanville EPR: the reactor has reached 100% of nuclear thermal power 14 December 2025 marks a major milestone : the Flamanville 3 reactor reached 100% nuclear thermal power at 11:37am and generated 1,669MW of gross electrical power*. The ramp-up to 100% nuclear thermal power follows the approval by the French nuclear safety and radiation protection authority (ASNR) on 12 December 2025, to go beyond the 80% threshold. Reaching the 100% mark for the first time enables testing of equipment at full power, taking of measurements and verifying that everything is functioning properly. Over the coming weeks, and as part of the start-up program, the power of the reactor will vary to continue testing at different power levels and an operation will be carried out on an internal electrical substation. This milestone reflects the...

BEIJING, Dec. 14, 2025 (GLOBE NEWSWIRE) — InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the phase IIb clinical study of novel BTK inhibitor orelabrutinib has met the primary endpoint in patients with systemic lupus erythematosus (SLE). InnoCare has also received approval from the Center for Drug Evaluation (CDE) to conduct a phase III registrational clinical trial. Orelabrutinib demonstrated outstanding efficacy and well-tolerated safety profile in patients with SLE who had received 48 weeks of treatment in the phase IIb study. A total of 187 patients were enrolled and randomized (1:1:1) into three groups: orelabrutinib 75 mg once-daily (QD), orelabrutinib 50 mg QD, and placebo. The primary endpoint of this study...

MAHIA, New Zealand, Dec. 13, 2025 (GLOBE NEWSWIRE) — Rocket Lab Corporation (Nasdaq: RKLB) (“Rocket Lab” or “the Company”), a global leader in launch services and space systems, today successfully launched its first dedicated mission for the Japan Aerospace Exploration Agency (JAXA) – a pivotal marker of Electron’s global importance for regular, reliable, and dedicated access to space. The “RAISE And Shine” mission lifted off from Rocket Lab Launch Complex 1 in New Zealand on December 14, 2025 at 03:09 UTC / 16:09 NZDT to successfully deploy the agency’s RApid Innovative payload demonstration SatellitE-4 (RAISE-4) spacecraft: a demonstration of eight technologies developed by private companies, universities, and research institutions throughout Japan. The mission was the first of two dedicated missions for JAXA’s Innovative Satellite...

QUEBEC CITY, Dec. 13, 2025 (GLOBE NEWSWIRE) — Robex Resources Inc. (“Robex” or the “Corporation”) (TSX-V: RBX, ASX: RXR) announces that, further to the announcement on December 10, 2025, it has filed an addendum (the “Addendum”) to the management information circular of the Corporation dated November 11, 2025 (the “Circular”). The Addendum provides certain information regarding the amending agreement (the “Amending Agreement”) entered into between Robex, Predictive Discovery Limited (“Predictive”) (ASX: PDI) and 9548-5991 Québec Inc. (“Acquireco”) to amend the previously announced arrangement agreement dated October 5, 2025 among Robex, Predictive and Acquireco (together with the Amending Agreement, the “Arrangement Agreement”), pursuant to which Acquireco, a direct wholly-owned subsidiary of Predictive, will acquire all of the...

VANCOUVER, British Columbia, Dec. 12, 2025 (GLOBE NEWSWIRE) — Cornish Metals Inc. (AIM/TSXV: CUSN) (“Cornish Metals”, “Cornish Canada” or the “Company”), a mineral exploration and development company focused on advancing its wholly owned and permitted South Crofty tin project in Cornwall, United Kingdom, is pleased to announce that the Company has obtained a final order from the Ontario Superior Court of Justice approving the previously announced re-domicile of the Company to the United Kingdom by way of a statutory plan of arrangement (the “Arrangement”). As previously disclosed by the Company, the Arrangement will result in the transfer all of the issued and outstanding common shares of the Company (each a “Cornish Canada Share”) to Cornish Metals plc (“Cornish UK”) in exchange for the issue to the Company’s shareholders of...

Not for distribution to U.S. news wire services or dissemination in the United States VANCOUVER, BC, Dec. 12, 2025 (GLOBE NEWSWIRE) — Fobi AI Inc. (FOBI:TSXV) (FOBIF: Pink) (the “Company” or “Fobi”), is pleased to announce that the British Columbia Securities Commission has granted a partial revocation order dated December 12, 2025 (the “Partial Revocation Order”) to the failure-to-file cease trade order issued in respect of the Company on November 1, 2024 (the “CTO”) to permit the Company to complete a non-brokered private placement financing (the “Offering”) of up to 30,000,000 units of the Company (“Units”) at a price per Unit of C$0.05 (the “Offering Price”) for aggregate gross proceeds of up to C$1,500,000. Each Unit shall consist of one (1) Common Share of the Company (each a “Share”) and one (1) Share...

– NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES – Vancouver, BC, Dec. 12, 2025 (GLOBE NEWSWIRE) — North America Niobium and Critical Minerals Corp. (CSE: NIOB) (FSE: IOR) (OTCQB: NIOMF) (“North American Niobium” or the “Company”) is pleased to announce, further to its news release of December 4, 2025, that the Company has closed the previously announced non-brokered private placement of flow-through common shares in the capital of the Company (each, an “FT Share”) by the issuance of 1,351,955 FT Shares at $1.45 per FT Share for gross proceeds of $1,960,334.75, exceeding the proposed amount previously announced (the “Oversubscribed Offering”) The gross proceeds from the issuance of the FT Shares will be used to incur eligible “Canadian exploration expenses” in Quebec that qualify as “flow-through...

The skilled nursing, assisted and senior living provider reiterates dedication to a financial restructuring process centered around current and future patients, residents and staff KENNETT SQUARE, Pa., Dec. 12, 2025 (GLOBE NEWSWIRE) — Following a court ruling on Thurs., Dec. 11 to reopen the auction process in Genesis Healthcare, Inc.’s (Genesis) and its affiliates’ ongoing chapter 11 bankruptcy proceedings, David Harrington, Executive Chairman of the Board of Genesis, reiterated the company’s commitment to securing long-term stability through the court-supervised chapter 11 proceedings, clarified inaccuracies in public conversations surrounding the process, and called on all interested parties to recognize – and respect – the hard work and dedication of the Genesis employees who are continuing to deliver services to the elderly...

TORONTO, Dec. 12, 2025 (GLOBE NEWSWIRE) — Rocky Shore Gold Ltd. (“Rocky Shore” or the “Company”) (CSE: RSG) is pleased to announce that, through a wholly-owned subsidiary, it has completed the previously announced purchase agreement for the acquisition of the Brady Property and made the first option payment due under the Huxter Lane Option Agreement (see press release dated December 2, 2025). In connection with the Brady Property Purchase Agreement, the Company made a cash payment of $75,000 and issued to the vendor 1,000,000 common shares of Rocky Shore. The vendor shall retain a 0.5% NSR which Rocky Shore’s subsidiary may repurchase, at any time, for $250,000 in cash. An underlying 2% NSR on the property exists, which can be repurchased, at any time, for $1,000,000 in cash. In connection with the Huxter Lane Option Agreement,...